Fleck PR

References (2)

Title : Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study - Nauck_2009_Int.J.Clin.Pract_63_46
Author(s) : Nauck MA , Ellis GC , Fleck PR , Wilson CA , Mekki Q
Ref : Int J Clin Pract , 63 :46 , 2009
Abstract : Nauck_2009_Int.J.Clin.Pract_63_46
ESTHER : Nauck_2009_Int.J.Clin.Pract_63_46
PubMedSearch : Nauck_2009_Int.J.Clin.Pract_63_46
PubMedID: 19125992

Title : Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy - Pratley_2009_Diabetes.Obes.Metab_11_167
Author(s) : Pratley RE , Kipnes MS , Fleck PR , Wilson C , Mekki Q
Ref : Diabetes Obes Metab , 11 :167 , 2009
Abstract : Pratley_2009_Diabetes.Obes.Metab_11_167
ESTHER : Pratley_2009_Diabetes.Obes.Metab_11_167
PubMedSearch : Pratley_2009_Diabetes.Obes.Metab_11_167
PubMedID: 19125778